Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23212908 | 1.00 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL28820045 | 1.00 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL19979060 | 0.86 | ALDH1A1 (0.37) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL29558146 | 0.86 | TSHR (0.48) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL19971983 | 0.86 | TSHR (0.48) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL5111434 | 0.84 | ALDH1A1 (0.48) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL23212814 | 0.84 | CES2 (0.41) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL2420963 | 0.84 | CYP1A2 (0.35) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL29959360 | 0.84 | CES2 (0.41) | CYP1A2CYP3A4CYP2D6NFKB1PNMT | |
| SCHEMBL1396928 | 0.84 | CES2 (0.41) | CYP1A2CYP3A4CYP2D6NFKB1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464645-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Palo Alto, Inc. (US) | 2012-06-20 | — | — | EP | claimed |
| EP-4041727-B1 | ATF6 MODULATORS AND USES THEREOF | ALTOS LABS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | TAY THERAPEUTICS LTD (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-08-21 | — | — | US | disclosed |
| EP-4558224-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-05-28 | — | — | EP | disclosed |
| CN-119823112-A | ATF6 modulators and uses thereof | 阿尔托斯实验室公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119751439-A | ATF6 modulators and uses thereof | 阿尔托斯实验室公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-116063283-B | 3-Amino indazole compound and application thereof | 暨南大学 | 2025-03-25 | — | — | CN | disclosed |
| CN-119570755-A | Ketone reductase mutant and application thereof in synthesis of (R) -1- (2, 6-dichlorophenyl) ethanol | 上海泓博尚奕药物技术有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-115135645-B | ATF6 modulators and uses thereof | 阿尔托斯实验室公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2009087305-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS | SANOFI-AVENTIS (FR) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009078999-A1 | IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156599-A1 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | disclosed |
| US-6951848-B2 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC., (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| EP-1377549-A1 | FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2002072549-A1 | FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-1996015672-A1 | FUNGICIDAL COMPOSITION | ZENECA LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
| WO-1996015671-A1 | HERBICIDES | ZENECA LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | CYP1A2 1323/4885CYP3A4 539/4885CYP2D6 696/4885 |
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | CYP1A2 1422/4885CYP3A4 538/4885CYP2D6 694/4885 |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, BRD4, PHKB | CYP1A2 3117/4885CYP3A4 3789/4885CYP2D6 3645/4885 |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, PHKB, BRD4 | CYP1A2 4517/4885CYP3A4 3927/4885CYP2D6 4476/4885 |
| US-20090156599-A1 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | TRPV1, TRPA1, TRPV4 | CYP1A2 2748/4885CYP3A4 1824/4885CYP2D6 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.